MSB.AX Live-Signale | Maximieren Sie Profite mit Getagraph.com

Live Chart Being Loaded With Signals

Commentary (28 Jun 2024 @ 08:10):
Our systems believe the stock currently is overvalued by -0.01% compare to its pairs and should correct downwards.

Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, the United Kingdom, and Switzerland...

Stats
Tagesvolumen	5.50M
Durchschnittsvolumen	10.92M
Marktkapitalisierung	1.10B
EPS	$-0.0191 ( Q2 \| 2023-12-31 )
Nächstes Ertragsdatum	( $0 ) 2024-07-29
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-8.25 (Sector) 0 (Industry) 0
ATR14	$0.00300 (0.30%)

ACW.AX 34.78%

ADO.AX 0.00%

AGH.AX -4.17%

ANP.AX -4.92%

ATH.AX 0.00%

AVE.AX 0.00%

BIT.AX 2.70%

BNO.AX -10.00%

BOT.AX -5.48%

CAN.AX 0.00%

CPH.AX 0.00%

CSL.AX 0.02%

CTE.AX 8.77%

CUV.AX 0.85%

CYP.AX 1.72%

DXB.AX 0.00%

ECS.AX 0.00%

EOF.AX -6.25%

GSS.AX 1.41%

IDT.AX 0.00%

IMC.AX 0.00%

IMM.AX -11.94%

IMU.AX 5.56%

IXC.AX -10.45%

KZA.AX 9.59%

LCT.AX 7.14%

LGP.AX -9.52%

MSB.AX 1.02%

MVP.AX -1.22%

MXC.AX 2.44%

NEU.AX 3.15%

NOX.AX -2.94%

NSB.AX 2.56%

OCC.AX 0.00%

OPT.AX -2.78%

OSL.AX 0.00%

PAA.AX 0.00%

PAB.AX 0.00%

PAR.AX -1.92%

PBP.AX 0.00%

PIQ.AX -2.22%

PTX.AX -2.56%

PXS.AX 3.70%

PYC.AX 0.00%

RAC.AX 1.11%

RCE.AX 5.26%

SPL.AX 9.20%

TLX.AX 1.36%

VBS.AX 0.00%

Korrelation (AI algo v.1.1b): Overvalued: -0.01% $0.990 paired level. (Der Algorithmus verfolgt in Echtzeit die Änderungen der am stärksten korrelierten Aktien und gibt eine sofortige Aktualisierung)

Volumen Korrelation

Lang: -0.04 (neutral)

Kurz: -0.71 (moderate negative)

Signal:(43.774) Neutral

Mesoblast Ltd Korrelation

10 Am meisten positiv korreliert

10 Am meisten negativ korreliert

Wussten Sie das?

Korrelation ist ein statistisches Maß, das die Beziehung zwischen zwei Variablen beschreibt. Es reicht von -1 bis 1, wobei -1 eine perfekte negative Korrelation (wenn eine Variable zunimmt, nimmt die andere ab) anzeigt, 1 eine perfekte positive Korrelation (wenn eine Variable zunimmt, nimmt die andere zu) und 0 keine Korrelation anzeigt (es besteht kein Zusammenhang zwischen den Variablen).

Korrelation kann verwendet werden, um die Beziehung zwischen beliebigen zwei Variablen zu analysieren, nicht nur zwischen Aktien. Es wird häufig in Bereichen wie Finanzen, Wirtschaft, Psychologie und mehr verwendet.

Mesoblast Ltd Korrelation - Währung/Rohstoff

-0.37
( neutral )

-0.66
( moderate negative )

0.00
( neutral )

0.56
( weak )

Mesoblast Ltd Finanzdaten

Annual	2023
Umsatz:	$7.50M
Bruttogewinn:	$-47.42M (-632.20 %)
EPS:	$-0.110

FY	2023
Umsatz:	$7.50M
Bruttogewinn:	$-47.42M (-632.20 %)
EPS:	$-0.110

FY	2023
Umsatz:	$0
Bruttogewinn:	$0 (0.00 %)
EPS:	$0

FY	2022
Umsatz:	$10.21M
Bruttogewinn:	$-53.36M (-522.58 %)
EPS:	$-0.140

Financial Reports:

No articles found.

Mesoblast Ltd Options Data

Calls

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Puts

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Mesoblast Ltd

Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, the United Kingdom, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells. The company offers Remestemcel-L that is in Phase III clinical trials for the treatment of systemic inflammatory diseases, including steroid refractory acute graft versus host disease, acute respiratory distress syndrome, and biologic refractory inflammatory bowel disease; and Remestemcel-L, which is in Phase III clinical trials to treat chronic heart failure and chronic low back pain due to degenerative disc disease. It is also developing MPC-300-IV to treat biologic refractory rheumatoid arthritis diabetic nephropathy; and MPC-25-IC for the treatment or prevention of acute myocardial infarction. The company has strategic partnerships with Tasly Pharmaceutical Group to offer MPC-150-IM for heart failure and MPC-25-IC for heart attacks in China; JCR Pharmaceuticals Co. Ltd. to treat wound healing in patients with epidermolysis bullosa; and Grünenthal to develops and commercializes cell therapy for the treatment of chronic low back pain. Mesoblast Limited was incorporated in 2004 and is headquartered in Melbourne, Australia.